JPWO2021240155A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021240155A5 JPWO2021240155A5 JP2022570422A JP2022570422A JPWO2021240155A5 JP WO2021240155 A5 JPWO2021240155 A5 JP WO2021240155A5 JP 2022570422 A JP2022570422 A JP 2022570422A JP 2022570422 A JP2022570422 A JP 2022570422A JP WO2021240155 A5 JPWO2021240155 A5 JP WO2021240155A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- antibody
- diseases
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims 20
- 150000001413 amino acids Chemical class 0.000 claims 19
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 19
- 229940024606 amino acid Drugs 0.000 claims 18
- 235000001014 amino acid Nutrition 0.000 claims 18
- 125000005647 linker group Chemical group 0.000 claims 17
- 229910052760 oxygen Inorganic materials 0.000 claims 14
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 9
- -1 methylene, ethylene, propylene Chemical group 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229960003646 lysine Drugs 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- HTFFMYRVHHNNBE-YFKPBYRVSA-N (2s)-2-amino-6-azidohexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCN=[N+]=[N-] HTFFMYRVHHNNBE-YFKPBYRVSA-N 0.000 claims 2
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 claims 2
- 125000006585 (C6-C10) arylene group Chemical group 0.000 claims 2
- MAEDLSNGVQYGPK-UHFFFAOYSA-N 2,2-diaminoacetic acid Chemical compound NC(N)C(O)=O MAEDLSNGVQYGPK-UHFFFAOYSA-N 0.000 claims 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 2
- 239000004952 Polyamide Substances 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 150000001719 carbohydrate derivatives Chemical class 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 229960002433 cysteine Drugs 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 2
- 150000002633 lipinski molecules Chemical class 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 125000004957 naphthylene group Chemical group 0.000 claims 2
- 229960003104 ornithine Drugs 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 229920002647 polyamide Polymers 0.000 claims 2
- 229920000728 polyester Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229960001153 serine Drugs 0.000 claims 2
- 229940126586 small molecule drug Drugs 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 150000003457 sulfones Chemical class 0.000 claims 2
- 229960002898 threonine Drugs 0.000 claims 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 claims 1
- KRCVJTNGGWBYEW-REOHCLBHSA-N (2s)-2-(2-diazohydrazinyl)propanoic acid Chemical compound OC(=O)[C@H](C)NN=[N+]=[N-] KRCVJTNGGWBYEW-REOHCLBHSA-N 0.000 claims 1
- PPDNGMUGVMESGE-JTQLQIEISA-N (2s)-2-amino-3-(4-ethynylphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(C#C)C=C1 PPDNGMUGVMESGE-JTQLQIEISA-N 0.000 claims 1
- JSXMFBNJRFXRCX-NSHDSACASA-N (2s)-2-amino-3-(4-prop-2-ynoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OCC#C)C=C1 JSXMFBNJRFXRCX-NSHDSACASA-N 0.000 claims 1
- GAJBPZXIKZXTCG-VIFPVBQESA-N (2s)-2-amino-3-[4-(azidomethyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(CN=[N+]=[N-])C=C1 GAJBPZXIKZXTCG-VIFPVBQESA-N 0.000 claims 1
- NEMHIKRLROONTL-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-azidophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N=[N+]=[N-])C=C1 NEMHIKRLROONTL-QMMMGPOBSA-N 0.000 claims 1
- NNWQLZWAZSJGLY-VKHMYHEASA-N (2s)-2-azaniumyl-4-azidobutanoate Chemical compound OC(=O)[C@@H](N)CCN=[N+]=[N-] NNWQLZWAZSJGLY-VKHMYHEASA-N 0.000 claims 1
- ZXSBHXZKWRIEIA-JTQLQIEISA-N (2s)-3-(4-acetylphenyl)-2-azaniumylpropanoate Chemical compound CC(=O)C1=CC=C(C[C@H](N)C(O)=O)C=C1 ZXSBHXZKWRIEIA-JTQLQIEISA-N 0.000 claims 1
- HAFSUVXZYWPXLT-BYPYZUCNSA-N (2s)-5-amino-2-(2-diazohydrazinyl)pentanoic acid Chemical compound NCCC[C@@H](C(O)=O)NN=[N+]=[N-] HAFSUVXZYWPXLT-BYPYZUCNSA-N 0.000 claims 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims 1
- NPSWHDAHNWWMEG-UHFFFAOYSA-N 2-aminohex-5-enoic acid Chemical compound OC(=O)C(N)CCC=C NPSWHDAHNWWMEG-UHFFFAOYSA-N 0.000 claims 1
- SCGJGNWMYSYORS-UHFFFAOYSA-N 2-azaniumylhex-5-ynoate Chemical compound OC(=O)C(N)CCC#C SCGJGNWMYSYORS-UHFFFAOYSA-N 0.000 claims 1
- HLVUBMYREUJGCL-UHFFFAOYSA-N 3-amino-2-oxobutanoic acid Chemical compound CC(N)C(=O)C(O)=O HLVUBMYREUJGCL-UHFFFAOYSA-N 0.000 claims 1
- QBLRHWLVSHLMSP-UHFFFAOYSA-N 3-bromopyrrole-2,5-dione Chemical compound BrC1=CC(=O)NC1=O QBLRHWLVSHLMSP-UHFFFAOYSA-N 0.000 claims 1
- BXRLWGXPSRYJDZ-UHFFFAOYSA-N 3-cyanoalanine Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 claims 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000011359 Chromosome disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000027205 Congenital disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 claims 1
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims 1
- DGYHPLMPMRKMPD-UHFFFAOYSA-N L-propargyl glycine Natural products OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 claims 1
- QLDVOCPEKYLEOT-DGKWVBSXSA-N NC(CCCCNC(OCC1[C@H]2[C@@H]1CCC#CCC2)=O)C(O)=O Chemical compound NC(CCCCNC(OCC1[C@H]2[C@@H]1CCC#CCC2)=O)C(O)=O QLDVOCPEKYLEOT-DGKWVBSXSA-N 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- QXUSFQCJGVVVJR-MLWJPKLSSA-N OC(=O)[C@@H]1CC(CC#C)CN1 Chemical compound OC(=O)[C@@H]1CC(CC#C)CN1 QXUSFQCJGVVVJR-MLWJPKLSSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000025157 Oral disease Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010039438 Salmonella Infections Diseases 0.000 claims 1
- XDSSPSLGNGIIHP-VKHMYHEASA-N Se-methyl-L-selenocysteine Chemical compound C[Se]C[C@H]([NH3+])C([O-])=O XDSSPSLGNGIIHP-VKHMYHEASA-N 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 208000037386 Typhoid Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960005261 aspartic acid Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 208000024971 chromosomal disease Diseases 0.000 claims 1
- 239000000562 conjugate Substances 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000011404 female reproductive system disease Diseases 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 229960002989 glutamic acid Drugs 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 229960002743 glutamine Drugs 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000021991 hereditary neoplastic syndrome Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 150000002443 hydroxylamines Chemical class 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000017517 male reproductive system disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000030194 mouth disease Diseases 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000019180 nutritional disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 229920000768 polyamine Polymers 0.000 claims 1
- 229920000570 polyether Polymers 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039447 salmonellosis Diseases 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 claims 1
- 235000016491 selenocysteine Nutrition 0.000 claims 1
- 229940055619 selenocysteine Drugs 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960004799 tryptophan Drugs 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 201000008297 typhoid fever Diseases 0.000 claims 1
- 229960004441 tyrosine Drugs 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Claims (25)
(ii)式(I):
Xは、O、NH、NRAおよびSから選択され;
Yは、C=O、C=NH、C=NRAおよびC=Sから選択され;
Rは、水素またはC1-20ヒドロカルビルであり;
RAは、C1-20ヒドロカルビルであり;
各Qは、-CH2(NMe(C=O)CH2)o-、-T1O(CH2CH2O)sT2-および-T1O(CH2CH2CH2O)sT2-から独立して選択され(ここで、T1は、二価のメチレン、エチレン、プロピレンまたはブチレン基から選択され、T2は、二価のメチレン、エチレン、プロピレンまたはブチレン基から選択される);
oは、0から100の整数であり;
sは、0から150の整数であり;
xは、1から6の整数であり;
各Zは、式(i)、(ii)、(iii)、(iv)または(v):
Zが式(i)または(ii)の基であるとき:
-AA-は、-AA-Hがアミノ酸の側鎖を表すような二価の部分であり、
各L1は、リンカー基であり;
各Bは、生物活性部分であり;
Zが式(iii)の基であるとき:
-AA=は、-AA=Oがアミノ酸の側鎖を表すような三価の部分であり;
各L2は、リンカー基であり;
各破線は、存在するか存在しないかのいずれかである結合を表し;
各Bは、生物活性部分であり;
Zが式(iv)の基であるとき:
-AA-は、-AA-CH=CH2または-AA-C≡CHがアミノ酸の側鎖を表すような二価の部分であり;
各L3は、リンカー基であり;
各破線は、存在するか存在しないかのいずれかである結合を表し;
各Bは、生物活性部分であり;およびZが式(v)の基であるとき:
-AA-は、-AA-N3がアミノ酸の側鎖を表すような二価の部分であり;
各L3は、リンカー基であり;
各破線は、存在するか存在しないかのいずれかである結合を表し;
各Bは、生物活性部分である)の群から独立して選択される)の繰り返し単位を含むポリマー;並びに
(iii)該抗体および該ポリマーの両方に共有結合しているポリマー-抗体リンカーを含む、抗体-薬物結合体。 (i) an antibody or antigen-binding fragment thereof;
(ii) Formula (I):
X is selected from O, NH, NR A and S;
Y is selected from C=O, C=NH, C=NR A and C=S;
R is hydrogen or C 1-20 hydrocarbyl;
R A is C 1-20 hydrocarbyl;
each Q is independently selected from -CH 2 (NMe(C=O)CH 2 ) o -, -T 1 O(CH 2 CH 2 O) s T 2 -, and -T 1 O(CH 2 CH 2 CH 2 O) s T 2 -, where T 1 is selected from a divalent methylene, ethylene, propylene, or butylene group, and T 2 is selected from a divalent methylene, ethylene, propylene, or butylene group;
o is an integer from 0 to 100;
s is an integer from 0 to 150;
x is an integer from 1 to 6;
Each Z has formula (i), (ii), (iii), (iv) or (v):
When Z is a group of formula (i) or (ii):
-AA- is a divalent moiety such that -AA-H represents the side chain of an amino acid;
Each L1 is a linker group;
Each B is a biologically active moiety;
When Z is a group of formula (iii):
-AA= is a trivalent moiety such that -AA=O represents the side chain of an amino acid;
Each L2 is a linker group;
Each dashed line represents a bond that is either present or absent;
Each B is a biologically active moiety;
When Z is a group of formula (iv):
-AA- is a divalent moiety such that -AA-CH= CH2 or -AA-C≡CH represents the side chain of an amino acid;
Each L3 is a linker group;
Each dashed line represents a bond that is either present or absent;
Each B is a biologically active moiety; and when Z is a group of formula (v):
-AA- is a divalent moiety such that -AA- N3 represents the side chain of an amino acid;
Each L3 is a linker group;
Each dashed line represents a bond that is either present or absent;
each B is a biologically active moiety); and (iii) a polymer-antibody linker covalently attached to both the antibody and the polymer.
-AA-、BおよびRは、請求項1において定義されるとおりであり;
各L4は、リンカー基であり;
各L5は、リンカー基であり;
各L6は、リンカー基であり;
各Aは、結合、アミノ酸、ペプチド、スルホネート、スルホンアミド、またはピロリン酸ジエステルから独立して選択され;
各X’は、O、NH、NRA’およびSから独立して選択され;
各R’は、独立して水素またはC1-20ヒドロカルビルであり;
各RA’は、独立してC1-20ヒドロカルビルであり;
各Q’は、-CH2(NMe(C=O)CH2)o’-、-T’1O(CH2CH2O)s’T’2-および-T’1O(CH2CH2CH2O)s’T’2-から独立して選択され(ここで、各T’1は、二価のメチレン、エチレン、プロピレンまたはブチレン基から独立して選択され、各T’2は、二価のメチレン、エチレン、プロピレンまたはブチレン基から独立して選択される)、描かれているQ’部分の左側は、Y’部分に共有結合しており、描かれているQ’部分の右側は、X’部分に共有結合しており;
各破線は、存在するか存在しないかのいずれかである結合を表し;
各o’は、独立して0から100の整数であり;
各s’は、独立して0から150の整数であり;
Q’が-T’1O(CH2CH2O)s’T’2-および-T’1O(CH2CH2CH2O)s’T’2-であるとき、各Y’は、O、NH、NRA’およびSから独立して選択され、Q’が-CH2(NMe(C=O)CH2)o’-であるとき、各Y’は、-(C=O)-O-、-(C=O)-S-、-(C=O)-NHおよび-(C=O)-NRA’-から独立して選択される)、請求項1に記載の抗体-薬物結合体。 The group of formula (ii) is of formula (vi):
-AA-, B and R are as defined in claim 1;
Each L4 is a linker group;
Each L5 is a linker group;
Each L6 is a linker group;
Each A is independently selected from a bond, an amino acid, a peptide, a sulfonate, a sulfonamide, or a pyrophosphate diester;
each X' is independently selected from O, NH, NR A' , and S;
each R' is independently hydrogen or C 1-20 hydrocarbyl;
each R A' is independently a C 1-20 hydrocarbyl;
each Q' is independently selected from -CH 2 (NMe(C=O)CH 2 ) o' -, -T' 1 O(CH 2 CH 2 O) s' T' 2 -, and -T' 1 O(CH 2 CH 2 CH 2 O) s' T' 2 -, where each T' 1 is independently selected from a divalent methylene, ethylene, propylene, or butylene group, and each T' 2 is independently selected from a divalent methylene, ethylene, propylene, or butylene group, and the left side of the depicted Q' moiety is covalently bonded to the Y' moiety and the right side of the depicted Q' moiety is covalently bonded to the X'moiety;
Each dashed line represents a bond that is either present or absent;
each o' is independently an integer from 0 to 100;
Each s' is independently an integer from 0 to 150;
The antibody-drug conjugate of claim 1, wherein when Q' is -T' 1 O(CH 2 CH 2 O) s' T' 2 - and -T' 1 O(CH 2 CH 2 CH 2 O) s' T' 2 -, each Y' is independently selected from O, NH, NR A' and S; and when Q' is -CH 2 (NMe(C═O)CH 2 ) o' -, each Y' is independently selected from -(C═O)-O-, -(C═O)-S-, -(C═O)-NH and -(C═O)-NR A' -.
(b)-AA=Oが、アミノ-2-ケト-酪酸、4-アセチルフェニルアラニンおよびホルミルグリシンから選択されるアミノ酸の側鎖を表すか;
(c)-AA-N3が、アジドリジン、アジドオルニチン、アジドノルロイシン、アジドアラニン、アジドホモアラニン、4-アジドフェニルアラニンおよび4-アジドメチルフェニルアラニンから選択されるアミノ酸の側鎖を表すか;または
(d)-AA-CH=CH2が、ホモアリルグリシンの側鎖を表すか;または
(e)-AA-C≡CHが、4-エチニルフェニルアラニン、4-プロパルギルオキシフェニルアラニン、プロパルギルグリシン、4-(2-プロピニル)プロリン、2-アミノ-6-({[(1R,8S)-ビシクロ[6.1.0]ノン-4-イン-9-イルメトキシ]カルボニル}アミノ)ヘキサン酸およびホモプロパルギルグリシンから選択されるアミノ酸の側鎖を表す、
請求項1または請求項2に記載の抗体-薬物結合体。 (a) -AA-H represents the side chain of an amino acid selected from serine, cysteine, threonine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, tyrosine, tryptophan, histidine, ornithine, hydroxytryptophan, homoserine, homocysteine, allothreonine, selenocysteine, selenohomocysteine, α-aminoglycine, diaminoacetic acid, 2,3-diaminopropionic acid and α,γ-diaminobutyric acid, preferably the side chain of an amino acid selected from serine, cysteine, threonine, lysine and ornithine, and most preferably the side chain of lysine; or (b) -AA═O represents the side chain of an amino acid selected from amino-2-keto-butyric acid, 4-acetylphenylalanine and formylglycine;
(c) -AA- N3 represents the side chain of an amino acid selected from azidolysine, azidoornithine, azidonorleucine, azidoalanine, azidohomoalanine, 4-azidophenylalanine and 4-azidomethylphenylalanine; or (d) -AA-CH= CH2 represents the side chain of homoallylglycine; or (e) -AA-C≡CH represents the side chain of an amino acid selected from 4-ethynylphenylalanine, 4-propargyloxyphenylalanine, propargylglycine, 4-(2-propynyl)proline, 2-amino-6-({[(1R,8S)-bicyclo[6.1.0]non-4-yn-9-ylmethoxy]carbonyl}amino)hexanoic acid and homopropargylglycine,
The antibody-drug conjugate according to claim 1 or 2.
V1は、
●は、-AA-への結合点を示し;
●●は、-L’-への結合点を示し;
Y1は、O、SおよびNHから選択され、好ましくはOであり;
Y2は、O、SおよびNHから選択され、好ましくはOであり;
RAは、C1-20ヒドロカルビルであり;
vは、1から100、好ましくは1から10の整数であり;
破線は、任意に存在する結合を表す)から選択され;
L’は、結合、C1-20アルキレン、C1-20アルケニレン、C1-20アルキニレン、C6-10アリーレン(例えばフェニレンまたはナフチレン)、C7-20アラルキレン、C3-10シクロアルキレン、C4-8ヘテロシクロアルキレン、C5-10ヘテロアリーレン、C6-20ヘテロアラルキレン、-(O-K)i-、-(NH-K)i-、-(NR’-K)i-、116から2000Daの分子量を有するポリエステル、114から2000Daの分子量を有するポリアミド、および部分-W-(ここで、H-W-OHは、アミノ酸または2から20個の天然または合成アミノ酸サブユニットを含有するペプチドである)から選択され;
V2は、-OV-、-NHV-、-NRAV-、-SV-、-S-、-VS-、-OVS-、-NHVS-、-NRAVS-、-SVS-、-V(C=O)-、-V-O(C=O)-、-V-NH(C=O)-、-V-NRA(C=O)-、-V-S(C=O)-、-V-(C=NH)-、V-O(C=NH)-、-V-NH(C=NH)-、-V-NRA(C=NH)-、-V-S(C=NH)-、-V-(C=NRA)-、-V-O(C=NRA)-、-V-NH(C=NRA)-、-V-NRA(C=NRA)-、-V-S(C=NRA)-、-OV(C=O)-、-OV-O(C=O)-、-OV-NH(C=O)-、-OV-NRA(C=O)-、-OV-S(C=O)-、-OV-(C=NH)-、-OV-O(C=NH)-、-OV-NH(C=NH)-、-OV-NRA(C=NH)-、-OV-S(C=NH)-、-OV-(C=NRA)-、-OV-O(C=NRA)-、-OV-NH(C=NRA)-、-OV-NRA(C=NRA)-、-OV-S(C=NRA)-、-NHV(C=O)-、-NHV-O(C=O)-、-NHV-NH(C=O)-、-NHV-NRA(C=O)-、-NHV-S(C=O)-、-NHV-(C=NH)-、NHV-O(C=NH)-、-NHV-NH(C=NH)-、-NHV-NRA(C=NH)-、-NHV-S(C=NH)-、-NHV-(C=NRA)-、-NHV-O(C=NRA)-、-NHV-NH(C=NRA)-、-NHV-NRA(C=NRA)-、-NHV-S(C=NRA)-、-NRAV(C=O)-、-NRAV-O(C=O)-、-NRAV-NH(C=O)-、-NRAV-NRA(C=O)-、-NRAV-S(C=O)-、-NRAV-(C=NH)-、-NRAV-O(C=NH)-、-NRAV-NH(C=NH)-、-NRAV-NRA(C=NH)-、-NRAV-S(C=NH)-、-NRAV(C=NRA)-、-NRAV-O(C=NRA)-、-NRAV-NH(C=NRA)-、-NRAV-NRA(C=NRA)-、-NRAV-S(C=NRA)-、-SV(C=O)-、-SV-O(C=O)-、-SV-NH(C=O)-、-SV-NRA(C=O)-、-SV-S(C=O)-、-SV-(C=NH)-、SV-O(C=NH)-、-SV-NH(C=NH)-、-SV-NRA(C=NH)-、-SV-S(C=NH)-、-SV-(C=NRA)-、-SV-O(C=NRA)-、-SV-NH(C=NRA)-、-SV-NRA(C=NRA)-、-SV-S(C=NRA)-、-J-O(C=O)-、-O-J-O(C=O)-、-S-J-O(C=O)-、-NH-J-O(C=O)-、-NRA-J-O(C=O)-、ポリエーテル、例えば76から2000Daの分子量を有するポリ(アルキレングリコール)、75から2000Daの分子量を有するポリアミン、116から2000Daの分子量を有するポリエステル、114から2000Daの分子量を有するポリアミド、および部分-W-(ここで、H-W-OHは、アミノ酸または2から20個の天然若しくは合成アミノ酸サブユニットを含有するペプチドである)から選択され;
Vは、C1-20アルキレン、C1-20アルケニレン、C1-20アルキニレン、C6-10アリーレン(例えばフェニレンまたはナフチレン)、C7-20アラルキレン、C3-10シクロアルキレン、C4-8ヘテロシクロアルキレン、C5-10ヘテロアリーレン、およびC6-20ヘテロアラルキレンから選択され;
Jは、糖置換基、および糖置換基に対してパラまたはオルトに、メチレン基または部分-(CH=CH)k-CH2-(ここで、kは、1から10の整数であり、さらに該メチレン基または部分-(CH=CH)k-CH2-は、生物活性部分Bに近い-O(C=O)-基に直接結合しており、フェニル環の炭素は、生物活性部分Bから遠位のリンカー基の残りに直接結合している)を有するフェニル基であり;
各Kは、同一または異なって、C1-10アルキレンを表し;
iは、1から100、好ましくは1から50、より好ましくは2から20の整数であり;RAは、C1-20ヒドロカルビルである)のリンカー部分であり;
好ましくは、L1が、-(C=O)-C(H)=N-NH-CH2-(C=O)-Val-Cit-PAB-(C=O)-、-(C=O)-C(H)=N-O-CH2-(C=O)-Val-Cit-PAB-(C=O)-、-(C=O)-C(H)=N-CH2-(C=O)-Val-Cit-PAB-(C=O)-、-(C=O)-CH2-NH-NH-CH2-(C=O)-Val-Cit-PAB-(C=O)-、-(C=O)-CH2-NH-O-CH2-(C=O)-Val-Cit-PAB-(C=O)-および-(C=O)-CH2-NH-CH2-(C=O)-Val-Cit-PAB-(C=O)-から選択される部分である)のリンカー部分であるか;または
(b)Zが式(vi)の基であり、L4が式(x)または(xi):
*は、-AA-への結合点を示し;
**は、-A-X’-Q’-Y’R’への結合点を示し;
***は、-Bへの結合点を示し;
V1、L’およびV2は、上記(a)において定義されるとおりであり;
X1は、O、S、およびNHから選択され;
X2は、O、S、およびNHから選択され;
X3は、O、S、およびNHから選択され;
RAは、C1-20ヒドロカルビルであり;
mは、0から6の整数であり;
pは、0から6の整数である)のリンカー部分である、
請求項1から14のいずれか一項に記載の抗体-薬物結合体。 (a) Z is a group of formula (ii) and L 1 is a group of formula -V 1 -L'-V 2 -, where:
V1 is
● indicates the point of attachment to -AA-;
indicates the point of attachment to -L'-;
Y 1 is selected from O, S and NH, preferably O;
Y2 is selected from O, S and NH, preferably O;
R A is C 1-20 hydrocarbyl;
v is an integer from 1 to 100, preferably from 1 to 10;
The dashed lines represent optionally present bonds;
L' is selected from a bond, C 1-20 alkylene, C 1-20 alkenylene, C 1-20 alkynylene, C 6-10 arylene (e.g. phenylene or naphthylene), C 7-20 aralkylene, C 3-10 cycloalkylene, C 4-8 heterocycloalkylene, C 5-10 heteroarylene, C 6-20 heteroaralkylene, -(O-K) i -, -(NH-K) i -, -(NR'-K) i -, polyesters having a molecular weight of from 116 to 2000 Da, polyamides having a molecular weight of from 114 to 2000 Da, and the moiety -W- (wherein H-W-OH is an amino acid or a peptide containing from 2 to 20 natural or synthetic amino acid subunits);
V 2 is -OV-, -NHV-, -NR A V-, -SV-, -S-, -VS-, -OVS-, -NHVS-, -NR A VS-, -SVS-, -V(C=O)-, -V-O(C=O)-, -V-NH(C=O)-, -V-NR A (C=O)-, -V-S(C=O)-, -V-(C=NH)-, V-O(C=NH)-, -V-NH(C=NH)-, -V-NR A (C=NH)-, -V-S(C=NH)-, -V-(C=NR A )-, -V-O(C=NR A )-, -V-NH(C=NR A )-, -V-NR A (C=NR A )-, -V-S(C=NR A )-, -OV(C=O)-, -OV-O(C=O)-, -OV-NH(C=O)-, -OV-NR A (C=O)-, -OV-S(C=O)-, -OV-(C=NH)-, -OV-O(C=NH)-, -OV-NH(C=NH)-, -OV-NR A (C=NH)-, -OV-S(C=NH)-, -OV-(C=NR A )-, -OV-O(C=NR A )-, -OV-NH(C=NR A )-, -OV-NR A (C=NR A )-, -OV-S(C=NR A )-, -NHV(C=O)-, -NHV-O(C=O)-, -NHV-NH(C=O)-, -NHV-NR A (C=O)-, -NHV-S(C=O)-, -NHV-(C=NH)-, NHV-O(C=NH)-, -NHV-NH(C=NH)-, -NHV-NR A (C=NH)-, -NHV-S(C=NH)-, -NHV-(C=NR A )-, -NHV-O(C=NR A )-, -NHV-NH(C=NR A )-, -NHV-NR A (C=NR A )-, -NHV-S(C=NR A )-, -NR A V(C=O)-, -NR A V-O(C=O)-, -NR A V-NH(C=O)-, -NR A V-NR A (C=O)-, -NR A V-S(C=O)-, -NR A V-(C=NH)-, -NR A V-O(C=NH)-, -NR A V-NH(C=NH)-, -NR A V-NR A (C=NH)-, -NR A V-S(C=NH)-, -NR A V(C=NR A )-, -NR A V-O(C=NR A )-, -NR A V-NH(C=NR A )-, -NR A V-NR A (C=NR A )-, -NR A V-S(C=NR A )-, -SV(C=O)-, -SV-O(C=O)-, -SV-NH(C=O)-, -SV-NR A (C=O)-, -SV-S(C=O)-, -SV-(C=NH)-, SV-O(C=NH)-, -SV-NH(C=NH)-, -SV-NR A (C=NH)-, -SV-S(C=NH)-, -SV-(C=NR A )-, -SV-O(C=NR A )-, -SV-NH(C=NR A )-, -SV-NR A (C=NR A )-, -SV-S(C=NR A )-, -J-O(C=O)-, -O-J-O(C=O)-, -S-J-O(C=O)-, -NH-J-O(C=O)-, -NR A -J-O(C=O)-, polyethers, for example poly(alkylene glycols) having a molecular weight of 76 to 2000 Da, polyamines having a molecular weight of 75 to 2000 Da, polyesters having a molecular weight of 116 to 2000 Da, polyamides having a molecular weight of 114 to 2000 Da, and the moiety -W-, where H-W-OH is an amino acid or a peptide containing 2 to 20 natural or synthetic amino acid subunits;
V is selected from C 1-20 alkylene, C 1-20 alkenylene, C 1-20 alkynylene, C 6-10 arylene (e.g., phenylene or naphthylene), C 7-20 aralkylene, C 3-10 cycloalkylene, C 4-8 heterocycloalkylene, C 5-10 heteroarylene, and C 6-20 heteroaralkylene;
J is a phenyl group having a sugar substituent and, para or ortho to the sugar substituent, a methylene group or moiety -(CH=CH) k - CH2- , where k is an integer from 1 to 10, and further wherein the methylene group or moiety -(CH=CH) k - CH2- is directly bonded to the -O(C=O)- group proximal to the biologically active moiety B, and a carbon of the phenyl ring is directly bonded to the remainder of the linker group distal to the biologically active moiety B;
each K is the same or different and represents a C 1-10 alkylene;
i is an integer from 1 to 100, preferably 1 to 50, more preferably 2 to 20; R A is a C 1-20 hydrocarbyl;
Preferably, L 1 is -(C=O)-C(H)=N-NH-CH 2 -(C=O)-Val-Cit-PAB-(C=O)-, -(C=O)-C(H)=N-O-CH 2 -(C=O)-Val-Cit-PAB-(C=O)-, -(C=O)-C(H)=N-CH 2 -(C=O)-Val-Cit-PAB-(C=O)-, -(C=O)-C(H)=N-CH 2 -(C=O)-Val-Cit-PAB-(C=O)-, -(C=O)-CH 2 -NH-NH-CH 2 -(C=O)-Val-Cit-PAB-(C=O)-, -(C=O)-CH 2 -NH-O-CH 2 -(C=O)-Val-Cit-PAB-(C=O)- and -(C=O)-CH 2 -NH-CH 2 -(C=O)-Val-Cit-PAB-(C=O)-; or (b) Z is a group of formula (vi) and L4 is of formula (x) or (xi):
* indicates the point of attachment to -AA-;
** indicates the point of attachment to -AX'-Q'-Y'R';
*** indicates the point of attachment to -B;
V 1 , L′ and V 2 are as defined in (a) above;
X 1 is selected from O, S, and NH;
X2 is selected from O, S, and NH;
X3 is selected from O, S, and NH;
R A is C 1-20 hydrocarbyl;
m is an integer from 0 to 6;
p is an integer from 0 to 6;
An antibody-drug conjugate according to any one of claims 1 to 14.
V3は、
L’は、請求項15において定義されるとおりであり;
V2は、請求項15において定義されるとおりであり;
好ましくは、L2は、=N-NH-CH2-(C=O)-Val-Cit-PAB-(C=O)-、=N-O-CH2-(C=O)-Val-Cit-PAB-(C=O)-、=N-CH2-(C=O)-Val-Cit-PAB-(C=O)-、-NH-NH-CH2-(C=O)-Val-Cit-PAB-(C=O)-、-NH-O-CH2-(C=O)-Val-Cit-PAB-(C=O)-および-NH-CH2-(C=O)-Val-Cit-PAB-(C=O)-から選択される部分である)のリンカー部分であるか;または
(b)Zが式(vii)の基であり、L5が式(xii)または(xiii):
V3 is
L' is as defined in claim 15;
V2 is as defined in claim 15;
Preferably, L 2 is a moiety selected from: =N-NH-CH 2 -(C=O)-Val-Cit-PAB-(C=O)-, =N-O-CH 2 -(C=O)-Val-Cit-PAB-(C=O)-, =N-CH 2 -(C=O)-Val-Cit-PAB-(C=O)-, -NH-NH-CH 2 -(C=O)-Val-Cit-PAB-(C=O)-, -NH-O-CH 2 -(C=O)-Val-Cit-PAB-(C=O)- and -NH-CH 2 -(C=O)-Val-Cit-PAB-(C=O)-; or (b) Z is a group of formula (vii) and L 5 is a group of formula (xii) or (xiii):
L’は、請求項15において定義されるとおりであり;
V2は、請求項15において定義されるとおりである)のリンカー部分であるか;または(b)Zが式(viii)または(ix)の基であり、L6が式(xii)または(xiii):
請求項1から14のいずれか一項に記載の抗体-薬物結合体。 (a) Z is a group of formula (iv) or (v) and L 3 is of formula -V 4 -L'-V 2 -, where V 4 is -(CH 2 ) v -(C=Y 2 ), where v and Y 2 are as defined in claim 15;
L' is as defined in claim 15;
V2 is as defined in claim 15); or (b) Z is a group of formula (viii) or (ix) and L6 is a group of formula (xii) or (xiii):
An antibody-drug conjugate according to any one of claims 1 to 14.
(I)は、前述の請求項のいずれかにおいて定義される式(I)の繰り返し単位であり;Abは、抗体またはその抗原結合断片であり;
Lは、請求項1、7または8のいずれか一項において定義されるポリマー-抗体リンカーであり;
R”は、OH、ORA、SH、SRA、NH2、NHRAおよびNRA 2から選択され;Eは、HおよびRAから選択され;
RAは、請求項1において定義されるとおりであり;
zは、1から50の整数である)を有する、請求項1から18のいずれか一項に記載の抗体-薬物結合体。 Formula (III) or (IV):
(I) is a repeat unit of formula (I) as defined in any of the preceding claims; Ab is an antibody or an antigen-binding fragment thereof;
L is a polymer-antibody linker as defined in any one of claims 1, 7 or 8;
R″ is selected from OH, OR A , SH, SR A , NH 2 , NHR A , and NR A 2 ; E is selected from H and RA ;
R A is as defined in claim 1;
The antibody-drug conjugate of any one of claims 1 to 18, wherein z is an integer from 1 to 50.
(ii)式(I):
Xは、O、NH、NRAおよびSから選択され、
Yは、C=O、C=NH、C=NRAおよびC=Sから選択され;
Rは、水素またはC1-20ヒドロカルビルであり;
RAは、C1-20ヒドロカルビルであり;
各Qは、-CH2(NMe(C=O)CH2)o-、-T1O(CH2CH2O)sT2-および-T1O(CH2CH2CH2O)sT2-から独立して選択され(ここで、T1は、二価のメチレン、エチレン、プロピレンまたはブチレン基から選択され、T2は、二価のメチレン、エチレン、プロピレンまたはブチレン基から選択される);
oは、0から100の整数であり;
sは、0から150の整数であり;
xは、1から6の整数であり;
各Zは、式(i)、(ii)、(iii)、(iv)または(v):
Zが式(i)または(ii)の基であるとき:
-AA-は、-AA-Hがアミノ酸の側鎖を表すような二価の部分であり;
各L1は、リンカー基であり;
各Bは、生物活性部分であり;
Zが式(iii)の基であるとき:
-AA=は、-AA=Oがアミノ酸の側鎖を表すような三価の部分であり;
各L2は、リンカー基であり;
各破線は、存在するか存在しないかのいずれかである結合を表し;
各Bは、生物活性部分であり;
Zが式(iv)の基であるとき:
-AA-は、-AA-CH=CH2または-AA-C≡CHがアミノ酸の側鎖を表すような二価の部分であり;
各L3は、リンカー基であり;
各破線は、存在するか存在しないかのいずれかである結合を表し;
各Bは、生物活性部分であり;および
Zが式(v)の基であるとき:
-AA-は、-AA-N3がアミノ酸の側鎖を表すような二価の部分であり;
各L3は、リンカー基であり;
各破線は、存在するか存在しないかのいずれかである結合を表し;
各Bは、生物活性部分である)の群から独立して選択される)の繰り返し単位を含むポリマー;並びに
(iii)該標的化剤および該ポリマーの両方に共有結合しているポリマー-標的化剤リンカー
を含む、標的化剤-薬物結合体。 (i) a targeting agent;
(ii) Formula (I):
X is selected from O, NH, NR A and S;
Y is selected from C=O, C=NH, C=NR A and C=S;
R is hydrogen or C 1-20 hydrocarbyl;
R A is C 1-20 hydrocarbyl;
each Q is independently selected from -CH 2 (NMe(C=O)CH 2 ) o -, -T 1 O(CH 2 CH 2 O) s T 2 -, and -T 1 O(CH 2 CH 2 CH 2 O) s T 2 -, where T 1 is selected from a divalent methylene, ethylene, propylene, or butylene group, and T 2 is selected from a divalent methylene, ethylene, propylene, or butylene group;
o is an integer from 0 to 100;
s is an integer from 0 to 150;
x is an integer from 1 to 6;
Each Z has formula (i), (ii), (iii), (iv) or (v):
When Z is a group of formula (i) or (ii):
-AA- is a divalent moiety such that -AA-H represents the side chain of an amino acid;
Each L1 is a linker group;
Each B is a biologically active moiety;
When Z is a group of formula (iii):
-AA= is a trivalent moiety such that -AA=O represents the side chain of an amino acid;
Each L2 is a linker group;
Each dashed line represents a bond that is either present or absent;
Each B is a biologically active moiety;
When Z is a group of formula (iv):
-AA- is a divalent moiety such that -AA-CH= CH2 or -AA-C≡CH represents the side chain of an amino acid;
Each L3 is a linker group;
Each dashed line represents a bond that is either present or absent;
Each B is a biologically active moiety; and when Z is a group of formula (v):
-AA- is a divalent moiety such that -AA- N3 represents the side chain of an amino acid;
Each L3 is a linker group;
Each dashed line represents a bond that is either present or absent;
each B is a biologically active moiety); and (iii) a polymer-targeting agent linker covalently attached to both the targeting agent and the polymer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2007926.5 | 2020-05-27 | ||
GB2007926.5A GB2594753B (en) | 2020-05-27 | 2020-05-27 | Antibody-drug conjugates |
PCT/GB2021/051285 WO2021240155A1 (en) | 2020-05-27 | 2021-05-26 | Antibody-drug conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2024516917A JP2024516917A (en) | 2024-04-18 |
JPWO2021240155A5 true JPWO2021240155A5 (en) | 2024-04-30 |
Family
ID=71406281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022570422A Pending JP2024516917A (en) | 2020-05-27 | 2021-05-26 | Antibody-drug conjugates |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230173092A1 (en) |
EP (1) | EP4157357A1 (en) |
JP (1) | JP2024516917A (en) |
KR (1) | KR20230017246A (en) |
CN (1) | CN115666653A (en) |
AU (1) | AU2021279380A1 (en) |
CA (1) | CA3176362A1 (en) |
GB (1) | GB2594753B (en) |
IL (1) | IL298439A (en) |
WO (1) | WO2021240155A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023047090A1 (en) * | 2021-09-21 | 2023-03-30 | Spirea Limited | Antibody-drug conjugates |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012301793A1 (en) * | 2011-08-30 | 2014-03-20 | Quanta Biodesign, Ltd. | Branched discrette PEG constructs |
ES2960741T3 (en) | 2014-10-24 | 2024-03-06 | Abzena Uk Ltd | Conjugates and conjugation reagents |
CA3006247A1 (en) * | 2015-11-25 | 2017-06-01 | Legochem Biosciences, Inc. | Conjugates comprising peptide groups and methods related thereto |
WO2018166529A1 (en) * | 2017-03-16 | 2018-09-20 | Chang Tse Wen | Linker units and molecular constructs comprising same |
-
2020
- 2020-05-27 GB GB2007926.5A patent/GB2594753B/en active Active
-
2021
- 2021-05-26 EP EP21731569.6A patent/EP4157357A1/en active Pending
- 2021-05-26 AU AU2021279380A patent/AU2021279380A1/en active Pending
- 2021-05-26 IL IL298439A patent/IL298439A/en unknown
- 2021-05-26 CA CA3176362A patent/CA3176362A1/en active Pending
- 2021-05-26 WO PCT/GB2021/051285 patent/WO2021240155A1/en unknown
- 2021-05-26 JP JP2022570422A patent/JP2024516917A/en active Pending
- 2021-05-26 US US17/999,815 patent/US20230173092A1/en active Pending
- 2021-05-26 KR KR1020227044874A patent/KR20230017246A/en active Search and Examination
- 2021-05-26 CN CN202180038130.2A patent/CN115666653A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2605407T3 (en) | Albumin bound conjugates comprising a fatty acid and PEG | |
JP4137184B2 (en) | Method for producing drug conjugate | |
JP2002543111A (en) | Amplification of folate-mediated targeting to tumor cells using polymers | |
JP4137183B2 (en) | Drug complex | |
JP5277439B2 (en) | Nucleic acid-containing polymer micelle complex | |
JP4067058B2 (en) | PEGylated HGF | |
US6951939B2 (en) | Multivalent platform molecules comprising high molecular weight polyethylene oxide | |
ES2364987T3 (en) | COPOLYMER OF BLOCKS FOR DRUG CONJUGATES AND THEIR PHARMACEUTICAL COMPOSITIONS. | |
WO2003076490A1 (en) | Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound | |
JP2008528549A (en) | Insulin derivatives conjugated with structurally well-defined branched polymers | |
JP5856069B2 (en) | Polymer derivatives of novel cytidine antimetabolites | |
JP2000503639A (en) | Branched hydrazone linkers | |
JP2011184442A (en) | Il-21 derivatives | |
BG63492B1 (en) | Methods for the preparation of monomer conjugates of kalicheamycin derivative/carrier | |
US9415114B2 (en) | Conformations of divergent peptides with mineral binding affinity | |
TWI618697B (en) | Compounds, linker-drugs and ligand-drug conjugates | |
CN108026271B (en) | Polymer conjugate of 6-coordinate platinum complex | |
CN112543752A (en) | Linker, antibody conjugate drug containing linker and use of linker | |
EP1279405A1 (en) | Drugs retained in target tissue over long time | |
JP2022502361A (en) | Drug complex containing quinoline derivatives | |
WO2023222031A1 (en) | Pharmaceutical composition for treating colorectal cancer and use thereof | |
JPWO2021240155A5 (en) | ||
CN109589415B (en) | Conjugate of polyethylene glycol-polypeptide and protein medicine | |
JPWO2020097325A5 (en) | ||
JP5189243B2 (en) | Drug complex and carrier for drug delivery |